ArticleAnnals of surgical oncology2025
Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic Testing for All Breast Cancer Patients: The GET FACTS Randomized Clinical Trial.JAMA network open · 2026Trial
- Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer by Age, Race, and Tumor Subtype.Annals of surgical oncology · 2026Article
- Clinical Performance of International and Korean Genetic Testing Criteria for Hereditary Breast Cancer: A Large-Scale Cohort Analysis of 2,188 Individuals.Journal of breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIt is unclear whether the American Society of Breast Surgeons' (ASBrS) guideline to offer genetic testing (GT) to all patients with breast cancer (BC) impacted contralateral prophylactic mastectomy (CPM) rates. We sought to describe the trends of GT and CPM rates and to determine predictors of CPM uptake.
methodsAfter retrospective review of two prospectively maintained institutional databases, we identified patients with unilateral stage 0-III BC who underwent surgery between January 2016 and July 2020. Trends in GT and CPM rates were described and multivariable logistic regression determined factors associated with CPM utilization.
resultsAmong 6062 women identified, 3242 (53.4%) had GT. From January 2016 to July 2020, GT rates increased significantly from 46.3% to 70.1% (p < 0.001), but were not impacted by release of the guidelines. The proportion of pathogenic/likely pathogenic variants (PVs) detected in BC-related genes did not change significantly (p = 0.115). Overall, 782/6062 (12.9%) patients underwent CPM. There was no significant change in the CPM rate (p = 0.527), including before (p =0.298) and after (p = 0.220) guideline release. The factors significantly associated with increased CPM rates were PVs in a BC-related gene, increasing number of relatives with BC, first-degree relative with ovarian cancer, younger age, and cT2-3 tumors (all p < 0.05). Conversely, GT alone did not impact CPM (adjusted odds ratio 1.152, 95% confidence interval 0.85-1.55; p = 0.350 untested compared with GT with negative results).
conclusionsDespite increasing GT rates, CPM rates were stable over time and were not associated with GT, indicating that offering GT to more patients does not necessarily increase CPM rates.
Indexed as
Identifiers
40111630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.